Preterm Birth study: Celestone + Celestone
Official title Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)
ClinicalTrials.gov ID: NCT05114096
What this study is testing
What is Celestone?
An investigational use of Celestone is being studied as a potential treatment to reduce risks in preterm birth. It is designed to accelerate fetal lung maturity by acting as a corticosteroid.
Also referred to as betamethasone.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out if a half‑strength dose of the steroid medication works as well as the standard double dose for helping premature babies breathe.
- Who it's for
- Pregnant people who are expected to deliver early (preterm).
- What's involved
- Participants will be randomly assigned to receive either one lower dose of the steroid drug or the usual two doses, with routine medical visits and monitoring until delivery.
- Time commitment
- A single treatment during pregnancy with follow‑up visits until the baby is born.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 55, women only
You may be able to join if
- Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and \<34 weeks and 6 days...
- Capable of giving informed, written consent.
You likely can't join if
- Contraindication to corticosteroids
- Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc).
- Previous participation in this trial (in a previous pregnancy)
- Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality)
- Demise of one or more fetuses after 14 weeks and 0 days
The study team makes the final eligibility decision.
Where it is enrolling
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Fredericton, New Brunswick, Canada
- Moncton, New Brunswick, Canada
- Halifax, Nova Scotia, Canada
- Hamilton, Ontario, Canada
- Kingston, Ontario, Canada
- London, Ontario, Canada
- Ottawa, Ontario, Canada
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- Québec, Quebec, Canada
- Sherbrooke, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Calgary, Alberta, Canada; Edmonton, Alberta, Canada; Fredericton, New Brunswick, Canada; Moncton, New Brunswick, Canada; Halifax, Nova Scotia, Canada; Hamilton, Ontario, Canada and 7 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.